Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05548647 · ClinicalTrials.gov registry record · Phase 4
Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
NCT05548647: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT05548647 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05548647, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
Study Summary
This study will evaluate the effect of semaglutide on eating behavior, appetite (hunger/fullness), and food liking in the long-term, as compared to placebo. All participants will receive lifestyle modification (diet and exercise) counseling, and will be prescribed the FDA-approved weight loss medication, semaglutide, or placebo (an inactive saline solution) for 72 weeks.
Interventions
- DRUG Placebo
- BEHAVIORAL Behavioral Treatment
- DRUG Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2022-07-26 |
| Est. Completion | 2025-05-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05548647
The ClinicalTrials.gov registry entry for NCT05548647 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05548647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05548647 about?
NCT05548647 is a clinical study titled "Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects". This study will evaluate the effect of semaglutide on eating behavior, appetite (hunger/fullness), and food liking in the long-term, as compared to placebo. All participants will receive lifestyle modification (diet and exercise) counseling, and will be prescribed the FDA-approved weight loss medica...
What is the current status of trial NCT05548647?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2022-07-26. Estimated completion is 2025-05-12.
What interventions are being tested in trial NCT05548647?
The interventions under investigation include: Placebo (DRUG), Behavioral Treatment (BEHAVIORAL), Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY] (DRUG).
Who is sponsoring clinical trial NCT05548647?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.